Fulgent Genetics, Inc.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Ming Hsieh
- Full Time Employees
- 1,313
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 4978 Santa Anita Avenue El Monte CA United States of America 91780
- IPO Date
- Sep 29, 2016
- CIK
- 0001674930
- Website
- fulgentgenetics.com
- Similar Companies
- Business
- Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Company News
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 5,986 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation
Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT